Chronic immune thrombocytopenic purpura in children overview of 60 patients

Background: A small percentage of children with Immune thrombocytopenic purpura (ITP) suffer from a clinically significant disease with severe thrombocytopenia that requires intervention. Treatment for these children presents a challenge as there are few known therapies that offer long-term remissio...

Full description

Bibliographic Details
Main Authors: Ahmed Hatem Sabhan, Mazin Faisal Al-Jadiry, Hasanein Habeeb Ghali, Wisam Majeed Abed, Salma Abbas Al-Hadad
Format: Article
Language:English
Published: Elsevier 2016-05-01
Series:Pediatric Hematology Oncology Journal
Subjects:
ITP
Online Access:http://www.sciencedirect.com/science/article/pii/S2468124516300079
id doaj-151d2fbb35b64eb7bc41515da1615c3e
record_format Article
spelling doaj-151d2fbb35b64eb7bc41515da1615c3e2020-11-24T23:17:55ZengElsevierPediatric Hematology Oncology Journal2468-12452016-05-011191210.1016/j.phoj.2016.04.002Chronic immune thrombocytopenic purpura in children overview of 60 patientsAhmed Hatem Sabhan0Mazin Faisal Al-Jadiry1Hasanein Habeeb Ghali2Wisam Majeed Abed3Salma Abbas Al-Hadad4Oncology Unit, Children's Welfare Teaching Hospital, Medical City, Baghdad, IraqOncology Unit, Department of Pediatrics, Children's Welfare Teaching Hospital, Baghdad College of Medicine, Medical City, Baghdad, IraqOncology Unit, Department of Pediatrics, Children's Welfare Teaching Hospital, Baghdad College of Medicine, Medical City, Baghdad, IraqOncology Unit, Children's Welfare Teaching Hospital, Medical City, Baghdad, IraqOncology Unit, Department of Pediatrics, Children's Welfare Teaching Hospital, Baghdad College of Medicine, Medical City, Baghdad, IraqBackground: A small percentage of children with Immune thrombocytopenic purpura (ITP) suffer from a clinically significant disease with severe thrombocytopenia that requires intervention. Treatment for these children presents a challenge as there are few known therapies that offer long-term remission, and all that are known have significant side effects and toxicities. Aim of the study: To evaluate the effects of a variety of treatment modalities on the clinical course, and long treatment outcomes in children with chronic ITP. Patients & methods: A study involved 60 children with chronic ITP who were referred to Hemato-Oncology unit/Children's Welfare Teaching Hospital/Medical City/Baghdad. Treatment of patients included steroid, Intravenous Immunoglobulins, Anti D immunoglobulin, 6-Mercaptopurine, Rituximab and splenectomy. The Period of data collection and analysis was from May 2009 to May 2011. Results: The most common presenting symptom was skin bleeding, seen in 42 (70%) patients. Thirty-four patients received one or more courses of steroids. Complete response was achieved in 7 (20.5%) patients while there was no response in 12 (35.2%) patients, Intravenous immunoglobulin was used for 5 patients, only one (16%) exhibited a good response. Anti D Immunoglobulin was used in six patients; only one (8.3%) patient got good response. Twelve patients received 6-mercaptopurine, only one (8.3%) patient had a partial response. Six patients received Rituximab; three (50%) had a partial response. Six patients underwent splenectomy; response was noted in 5/6 (83.3%) patients. At the end of the study; complete response was seen in 13 (22.4%) patients, partial in 19 (31.6%), no response in 28 (46.7%) patients. Conclusions: Splenectomy is the most effective treatment modality when treating children with chronic ITP whose symptoms are severe.http://www.sciencedirect.com/science/article/pii/S2468124516300079ITPChronicChildren
collection DOAJ
language English
format Article
sources DOAJ
author Ahmed Hatem Sabhan
Mazin Faisal Al-Jadiry
Hasanein Habeeb Ghali
Wisam Majeed Abed
Salma Abbas Al-Hadad
spellingShingle Ahmed Hatem Sabhan
Mazin Faisal Al-Jadiry
Hasanein Habeeb Ghali
Wisam Majeed Abed
Salma Abbas Al-Hadad
Chronic immune thrombocytopenic purpura in children overview of 60 patients
Pediatric Hematology Oncology Journal
ITP
Chronic
Children
author_facet Ahmed Hatem Sabhan
Mazin Faisal Al-Jadiry
Hasanein Habeeb Ghali
Wisam Majeed Abed
Salma Abbas Al-Hadad
author_sort Ahmed Hatem Sabhan
title Chronic immune thrombocytopenic purpura in children overview of 60 patients
title_short Chronic immune thrombocytopenic purpura in children overview of 60 patients
title_full Chronic immune thrombocytopenic purpura in children overview of 60 patients
title_fullStr Chronic immune thrombocytopenic purpura in children overview of 60 patients
title_full_unstemmed Chronic immune thrombocytopenic purpura in children overview of 60 patients
title_sort chronic immune thrombocytopenic purpura in children overview of 60 patients
publisher Elsevier
series Pediatric Hematology Oncology Journal
issn 2468-1245
publishDate 2016-05-01
description Background: A small percentage of children with Immune thrombocytopenic purpura (ITP) suffer from a clinically significant disease with severe thrombocytopenia that requires intervention. Treatment for these children presents a challenge as there are few known therapies that offer long-term remission, and all that are known have significant side effects and toxicities. Aim of the study: To evaluate the effects of a variety of treatment modalities on the clinical course, and long treatment outcomes in children with chronic ITP. Patients & methods: A study involved 60 children with chronic ITP who were referred to Hemato-Oncology unit/Children's Welfare Teaching Hospital/Medical City/Baghdad. Treatment of patients included steroid, Intravenous Immunoglobulins, Anti D immunoglobulin, 6-Mercaptopurine, Rituximab and splenectomy. The Period of data collection and analysis was from May 2009 to May 2011. Results: The most common presenting symptom was skin bleeding, seen in 42 (70%) patients. Thirty-four patients received one or more courses of steroids. Complete response was achieved in 7 (20.5%) patients while there was no response in 12 (35.2%) patients, Intravenous immunoglobulin was used for 5 patients, only one (16%) exhibited a good response. Anti D Immunoglobulin was used in six patients; only one (8.3%) patient got good response. Twelve patients received 6-mercaptopurine, only one (8.3%) patient had a partial response. Six patients received Rituximab; three (50%) had a partial response. Six patients underwent splenectomy; response was noted in 5/6 (83.3%) patients. At the end of the study; complete response was seen in 13 (22.4%) patients, partial in 19 (31.6%), no response in 28 (46.7%) patients. Conclusions: Splenectomy is the most effective treatment modality when treating children with chronic ITP whose symptoms are severe.
topic ITP
Chronic
Children
url http://www.sciencedirect.com/science/article/pii/S2468124516300079
work_keys_str_mv AT ahmedhatemsabhan chronicimmunethrombocytopenicpurpurainchildrenoverviewof60patients
AT mazinfaisalaljadiry chronicimmunethrombocytopenicpurpurainchildrenoverviewof60patients
AT hasaneinhabeebghali chronicimmunethrombocytopenicpurpurainchildrenoverviewof60patients
AT wisammajeedabed chronicimmunethrombocytopenicpurpurainchildrenoverviewof60patients
AT salmaabbasalhadad chronicimmunethrombocytopenicpurpurainchildrenoverviewof60patients
_version_ 1725582663830470656